AR027694A1 - Uso de la proteina mia para el tratamiento de enfermedades autoinmunes - Google Patents

Uso de la proteina mia para el tratamiento de enfermedades autoinmunes

Info

Publication number
AR027694A1
AR027694A1 ARP010101332A ARP010101332A AR027694A1 AR 027694 A1 AR027694 A1 AR 027694A1 AR P010101332 A ARP010101332 A AR P010101332A AR P010101332 A ARP010101332 A AR P010101332A AR 027694 A1 AR027694 A1 AR 027694A1
Authority
AR
Argentina
Prior art keywords
treatment
protein
autoimmune diseases
mia
patients
Prior art date
Application number
ARP010101332A
Other languages
English (en)
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of AR027694A1 publication Critical patent/AR027694A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de MIA para prevenir enfermedades inflamatorias y en particular su uso en el tratamiento de la destruccion cronica del cartílago articular. Másespecíficamente MIA puede ser usada para inducir la tolerancia específica de las células T al antígeno MIA en pacientes que presentan artritis reumatoide.
ARP010101332A 2000-03-23 2001-03-22 Uso de la proteina mia para el tratamiento de enfermedades autoinmunes AR027694A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00201063 2000-03-23

Publications (1)

Publication Number Publication Date
AR027694A1 true AR027694A1 (es) 2003-04-09

Family

ID=8171248

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101332A AR027694A1 (es) 2000-03-23 2001-03-22 Uso de la proteina mia para el tratamiento de enfermedades autoinmunes

Country Status (19)

Country Link
US (1) US20030091583A1 (es)
EP (1) EP1267907A1 (es)
JP (1) JP2003527435A (es)
KR (1) KR20020089404A (es)
CN (1) CN1418105A (es)
AR (1) AR027694A1 (es)
AU (1) AU783170B2 (es)
BR (1) BR0109455A (es)
CA (1) CA2399028A1 (es)
CZ (1) CZ20023187A3 (es)
HU (1) HUP0300997A2 (es)
IL (1) IL150679A0 (es)
MX (1) MXPA02008889A (es)
NO (1) NO20024458D0 (es)
NZ (1) NZ520346A (es)
PL (1) PL358132A1 (es)
RU (1) RU2002128351A (es)
SK (1) SK13692002A3 (es)
WO (1) WO2001070253A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076965A1 (en) * 2002-10-16 2004-04-22 Bosserhoff Anja Katrin MIA-2 protein
US8026354B2 (en) * 2005-11-23 2011-09-27 Institut Pasteur Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use
BRPI0706575B8 (pt) * 2006-01-13 2021-05-25 Univ Indiana Res & Tech Corp uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado.
NZ594540A (en) * 2008-07-16 2012-01-12 Baylor Res Inst Hiv vaccine based on targeting maximized gag and nef antigen to dendritic cells using antibodies
RU2588658C2 (ru) 2010-04-27 2016-07-10 ЭсСиАйЭл Текнолоджи ГмбХ Стабильные водные композиции белка mia/cd-rap
ITRM20110134A1 (it) * 2011-03-22 2012-09-23 Matteo Bordignon Inibitori di mia (attività inibitoria melanoma) per identificare, prevenire e curare la vitiligine
SG11201405848UA (en) * 2012-03-23 2014-10-30 Univ Queensland Immunomodulatory agent and uses therefor
ITRM20120339A1 (it) * 2012-07-16 2014-01-17 Matteo Bordignon Uso di mia (attività inibitoria melanoma) per il trattamento della iper-pigmentazione cutanea e per lo sbiancamento cosmetico della pelle
CN116327971A (zh) * 2023-03-02 2023-06-27 暨南大学附属第一医院（广州华侨医院） 一种靶向cd74+促炎型巨噬细胞的药物载体及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0947583A3 (de) * 1993-07-20 2000-05-03 Boehringer Mannheim Gmbh Expressionsaktivierende Nukleinsäurefragmente des Melanom-inhibierenden Proteins (MIA)
EP1007663A2 (en) * 1997-01-21 2000-06-14 Human Genome Sciences, Inc. Human proteins
DE59810255D1 (de) * 1997-10-16 2004-01-08 Scil Technology Holding Gmbh Nachweis von Knorpelerkrankungen mit MIA

Also Published As

Publication number Publication date
CN1418105A (zh) 2003-05-14
WO2001070253A1 (en) 2001-09-27
SK13692002A3 (sk) 2003-02-04
AU4247601A (en) 2001-10-03
IL150679A0 (en) 2003-02-12
JP2003527435A (ja) 2003-09-16
US20030091583A1 (en) 2003-05-15
AU783170B2 (en) 2005-09-29
KR20020089404A (ko) 2002-11-29
RU2002128351A (ru) 2004-03-27
CZ20023187A3 (cs) 2003-01-15
NZ520346A (en) 2004-07-30
MXPA02008889A (es) 2003-04-25
CA2399028A1 (en) 2001-09-27
NO20024458L (no) 2002-09-18
BR0109455A (pt) 2003-06-03
NO20024458D0 (no) 2002-09-18
PL358132A1 (en) 2004-08-09
HUP0300997A2 (hu) 2003-07-28
WO2001070253A8 (en) 2003-03-20
EP1267907A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
AR037695A1 (es) Composicion para el tratamiento del cabello
AR095541A1 (es) Muteínas de interleucina-2 (il-2) para la expansión de células t reguladoras
BRPI0506829A (pt) composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
ES2114786B1 (es) Tromboyetina. trombopoyetina recombinante y procedimiento de obtencion.
ATE490275T1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
PT1296603E (pt) Dispositivo para fixacao de segmentos osseos separados em virtude de uma fractura
ES2650463T3 (es) Tratamiento de enfermedades inflamatorias con ACE2
CY1109203T1 (el) Ενδοφθαλμιος φακος και ο εγχυτηρας του
TR200101205T1 (tr) ímmn hastalìklarìn tedavisi i‡in bir farmas”tik terkip
ATE451460T1 (de) Antikörpermoleküle mit spezifizität für menschlichen tumornekrosefaktor-alpha, und deren verwendung
BR0313492A (pt) Formulação de anticorpos humanos para tratar distúrbios associados ao tnf-alfa
BRPI0411013A (pt) implante para uso na fusão de estruturas ósseas adjacentes, método de tratar um organismo para promover fusão de estruturas ósseas adjacentes e sistema para uso na fusão de estruturas ósseas adjacentes
CL2008000935A1 (es) Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
CL2007001665A1 (es) Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
WO2004078098A3 (en) Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
FI971756A (fi) CD23:een sitoutuvia aineita
AR026059A1 (es) Virus de plantas modificadas y metodos para su uso
AR027694A1 (es) Uso de la proteina mia para el tratamiento de enfermedades autoinmunes
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
PE20030473A1 (es) Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular
SV2003001183A (es) Anticuerpos de interluquina-1 beta ref.x-14900
ES2103493T3 (es) Uso de parathormona, de sus fragmentos biologicamente activos y de peptidos relacionados para el tratamiento del embarazo.
BR112022006817A2 (pt) Anticorpos direcionados a flt3 e uso dos mesmos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal